Mesoblast Limited (MESO) vs uniQure N.V. (QURE)

Mesoblast Limited and uniQure N.V. are both Biotechnology companies. Mesoblast Limited and uniQure N.V. are of similar size ($1.7B and $1.7B). uniQure N.V. grew revenue faster over the last twelve months: 28.0% against −26.5%. Mesoblast Limited has the higher net margin (−1,091.7% vs −1,154.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Mesoblast Limited leads on 11 and uniQure N.V. on 6.

Valuation

Metric MESO QURE Biotechnology median
P/E n/m n/m 11.36
P/S 136.96 83.50 9.12
P/B 1.79 5.71 2.14
Price to free cash flow n/m n/m 26.34
EV/EBITDA n/m n/m 0.62
EV/Sales 136.55 53.26 8.56
Earnings yield (8.48%) (14.55%) (34.18%)
Free cash flow yield (8.21%) (11.59%) (23.62%)

Profitability

Metric MESO QURE Biotechnology median
Gross margin (269.72%) 93.85% 67.24%
Operating margin (826.28%) (1,001.74%) 0.00%
Net margin (1,091.71%) (1,154.84%) 0.00%
Free cash flow margin 0.00% (956.80%) 0.00%
Return on equity 0.00% (88.99%) (50.28%)
Return on assets 0.00% (25.47%) (45.89%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MESO QURE Biotechnology median
Revenue growth (TTM) (26.54%) 28.04% 6.96%
EPS growth (last fiscal year) 48.24% 29.67% 29.86%
Revenue growth, 5-year CAGR 74.39% (15.57%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MESO QURE Biotechnology median
Debt to equity 0.22 0.17 0.00
Current ratio 1.58 11.52 4.72
Net debt to EBITDA (0.67) 3.36 1.01

Dividend

Metric MESO QURE Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric MESO QURE Biotechnology median
Market cap 1.70b 1.73b 167.45m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack